BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

RENATA

All Eps Dividend Board Agm Q1 Q2 Q3

RENATA 15-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 13.97 for July-September 2020 as against Tk. 11.62 for July-September 2019; Consolidated NOCFPS was Tk. 7.48 for July-September 2020 as against Tk. 17.42 for July-September 2019. Consolidated NAV per share was Tk. 259.89 as on September 30, 2020 and Tk. 245.65 as on June 30, 2020.

RENATA 11-Nov-2020

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle from 12.11.2020 to 15.11.2020. Trading of the shares of the Company will remain suspended on record date i.e., 16.11.2020.

RENATA 09-Nov-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2020 at 11:30 AM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.

RENATA 28-Oct-2020

(Continuation news of RENATA): and Renata Limited in its separate meetings held on 11 November 2019 and 13 November 2019 approved the amalgamation of the Company with Renata Oncology Limited, whereby the Subsidiary will merge with the Company and the Company shall be the surviving entity. Our opinion is not modified in respect of this matter. The financial statements reflect financial result of the amalgamated entity. (end)

RENATA 28-Oct-2020

The auditor of Renata Ltd has given the following Emphasis of Matter in the audit report of the Company prepared for the year ended on 30 June, 2020. Emphasis of Matter: We draw attention to note 1.3 to the consolidated financial statements which describe the amalgamation of the fully owned subsidiary Renata Oncology Limited with the Company. The Board of Directors of Renata Oncology Limited (cont.1)

RENATA 27-Oct-2020

(Continuation news of RENATA): If anyone fails to update his/her e-TIN before the Record Date, disbursement of respective cash dividend will be subject to deduction of AIT @ 15% instead of 10% as per regulation. The Company has also requested the shareholders to check and update their BOID's e-mail address, mobile number and Bank Accounts detail alone with Routing Number to get Dividend online through BEFTN system. (end)

RENATA 27-Oct-2020

The Company has requested the shareholders to update their 12 digits e-Tin Numbers through respective DPs and shareholders bearing Folio Number are requested to submit their 12 digits e-Tin certificate to the Share Department of the Company by November 16, 2020. (cont.)

RENATA 27-Oct-2020

There will be no price limit on the trading of the shares of the Company today (27.10.2020) following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.

RENATA 27-Oct-2020

(Continuation news of RENATA): iii) Bonus shares is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit the earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post-dividend retained earning become negative or a debit balance. (end)

RENATA 27-Oct-2020

(Continuation news of RENATA): The Company has also informed that i) Bonus shares has been recommended in view to utilize its retained amount as capital for manufacturing facility expansion. ii) Bonus shares is declared out of accumulated profit. (cont.2)

Previous Next page